Singapore markets open in 3 hours 2 minutes
Straits Times Index
3,330.81 +0.80 (+0.02%) S&P 500
5,352.96 -1.07 (-0.02%) Dow
38,886.17 +78.84 (+0.20%) Nasdaq
17,173.12 -14.78 (-0.09%) Bitcoin USD
70,742.24 -379.23 (-0.53%) CMC Crypto 200
1,510.59 -14.21 (-0.93%)
Alkermes PLC (8AK.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
At close: 09:09PM CEST
| Previous close | 21.60 |
| Open | 21.60 |
| Bid | 22.20 x 100000 |
| Ask | 22.40 x 100000 |
| Day's range | 22.00 - 22.20 |
| 52-week range | 20.07 - 30.00 |
| Volume | |
| Avg. volume | 24 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 22 Jul 2024 - 26 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireAlkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy. The data are being presented at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston.
ZacksWhy Is Alkermes (ALKS) Down 2.7% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.
© 2024 Yahoo. All rights reserved.